Tadomon 250 mg tablete s produljenim oslobađanjem
| Name | Tadomon 250 mg tablete s produljenim oslobađanjem |
|---|---|
| Marketing Authorisation Number | HR-H-239998607 |
| Active Substance | tapentadoltartarat |
| Composition | jedna tableta s produljenim oslobađanjem sadrži 250 mg tapentadola (u obliku tapentadoltartarata) |
| Pharmaceutical Form | Tableta s produljenim oslobađanjem |
| Manufacturer | Laboratorios Liconsa S.A., Azuqueca de Henares, Guadalajara, Španjolska G.L. Pharma GmbH, Lannach, Austrija |
| Marketing Authorisation Holder | G.L. Pharma GmbH, Schlossplatz 1, Lannach, Austrija |
| Marketing Authorisation Date | 22.03.2024 |
| MA Period of Validity | 07.07.2027 |
| Classification Number | UP/I-530-09/21-01/71 |
| Registration Number | 381-12-01/70-24-11 |
| Prescription | na recept |
| Type of prescription | poseban recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | N02AX06 |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
